Jubilant Ingrevia Limited — Investor Meet, 10-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Ingrevia reported Q2 FY26 revenue of Rs 1,121 Cr (+7% YoY) and PAT of Rs 70 Cr (+18% YoY). H1 FY26 PAT grew 34% to Rs 145 Cr. Specialty Chemicals segment leads growth with double-digit YoY revenue and strong margins, securing 10+ new molecules for future Rs 1,200 Cr+ peak annual revenues. Nutrition volumes grew, but pricing pressure impacted margins. Chemical Intermediates saw highest sales in six quarters, gaining market share. The company is confident about H2 FY26, driven by Specialty Chemicals, Nutrition, and a major CDMO order from early 2026. New MPP groundbreaking reflects growth plans.